CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth

Experimental Hematology

Volumn 39, Issue 3, 2011, Pages 282-292

  Beider, Katia ^a   Begin, Michal ^a   Abraham, Michal ^a   Wald, Hanna ^a   Weiss, Ido D ^a   Wald, Ori ^a   Pikarsky, Eli ^a   Zeira, Evelyne ^a   Eizenberg, Orly ^b   Galun, Eithan ^a   Hardan, Izhar ^c   Engelhard, Dan ^a   Nagler, Arnon ^c   Peled, Amnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Science Park   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BKT 140; BORTEZOMIB; CASPASE 3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DOUBLE STRANDED DNA; INTERLEUKIN 6; PLERIXAFOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; HUMAN; HUMAN CELL; LEUKEMIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHEMOKINE CXCL12; HETEROCYCLIC COMPOUNDS; HL-60 CELLS; HUMANS; JURKAT CELLS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PEPTIDES; RECEPTORS, CXCR4;

ANIMALIA;

EID: 79951875085     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.11.010     Document Type: Article

References (48)

1. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
2. Loetscher P., Moser B., Baggiolini M. Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv Immunol 2000, 74:127-180.
3. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
4. Geminder H., Sagi-Assif O., Goldberg L., et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001, 167:4747-4757.
5. Koshiba T., Hosotani R., Miyamoto Y., et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000, 6:3530-3535.
6. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
7. Juarez J., Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 2004, 19:299-309.
8. Rombouts E.J., Pavic B., Lowenberg B., Ploemacher R.E. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104:550-557.
9. Voermans C., van Heese W.P., de Jong I., Gerritsen W.R., van Der Schoot C.E. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 2002, 16:650-657.
10. Spoo A.C., Lubbert M., Wierda W.G., Burger J.A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109:786-791.
11. Sanz-Rodriguez F., Hidalgo A., Teixido J. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001, 97:346-351.
12. Matsunaga T., Takemoto N., Sato T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 2003, 9:1158-1165.
13. Hideshima T., Chauhan D., Hayashi T., et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002, 1:539-544.
14. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
15. Ganju R.K., Brubaker S.A., Meyer J., et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998, 273:23169-23175.
16. Herbein G., Mahlknecht U., Batliwalla F., et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998, 395:189-194.
17. Ullrich C.K., Groopman J.E., Ganju R.K. HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 2000, 96:1438-1442.
18. Tamamura H., Xu Y., Hattori T., et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 1998, 253:877-882.
19. Tamamura H., Hiramatsu K., Mizumoto M., et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Org Biomol Chem 2003, 1:3663-3669.
20. Lili J., Yuchen S., Zhengtao W. The chemokine SDF-1alpha suppresses fibronectin-mediated in vitro lymphocytes adhesion. Mol Cells 2006, 22:308-313.
21. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
22. Zannettino A.C., Farrugia A.N., Kortesidis A., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005, 65:1700-1709.
23. Trent J.O., Wang Z.X., Murray J.L., et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 2003, 278:47136-47144.
24. Zhang W.B., Navenot J.M., Haribabu B., et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002, 277:24515-24521.
25. Beider K., Abraham M., Begin M., et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS ONE 2009, 4:e5125.
26. van de Donk N.W., Lokhorst H.M., Bloem A.C. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005, 19:2177-2185.
27. Trushin S.A., Algeciras-Schimnich A., Vlahakis S.R., et al. Glycoprotein 120 binding to CXCR4 causes p38-dependent primary T cell death that is facilitated by, but does not require cell-associated CD4. J Immunol 2007, 178:4846-4853.
28. Bachis A., Aden S.A., Nosheny R.L., Andrews P.M., Mocchetti I. Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 2006, 26:6771-6780.
29. Kim R., Emi M., Tanabe K., Murakami S., Uchida Y., Arihiro K. Regulation and interplay of apoptotic and non-apoptotic cell death. J Pathol 2006, 208:319-326.
30. Fox R., Aubert M. Flow cytometric detection of activated caspase-3. Methods Mol Biol 2008, 414:47-56.
31. Rubin J.B., Kung A.L., Klein R.S., et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513-13518.
32. Smith M.C., Luker K.E., Garbow J.R., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
33. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971.
34. Lapteva N., Yang A.G., Sanders D.E., Strube R.W., Chen S.Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89.
35. Liang Z., Wu T., Lou H., et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004, 64:4302-4308.
36. Kyle R.A., Rajkumar S.V. Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
37. Alsayed Y., Ngo H., Runnels J., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
38. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
39. Tavor S., Petit I., Porozov S., et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004, 64:2817-2824.
40. Zeng Z., Samudio I.J., Munsell M., et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 2006, 5:3113-3121.
41. Fierro F.A., Brenner S., Oelschlaegel U., et al. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia 2009, 23:393-396.
42. Azab A.K., Runnels J.M., Pitsillides C., et al. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
43. Juarez J., Bradstock K.F., Gottlieb D.J., Bendall L.J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003, 17:1294-1300.
44. Roggero R., Robert-Hebmann V., Harrington S., et al. Binding of human immunodeficiency virus type 1 gp120 to CXCR4 induces mitochondrial transmembrane depolarization and cytochrome c-mediated apoptosis independently of Fas signaling. J Virol 2001, 75:7637-7650.
45. Garg H., Blumenthal R. HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir. J Leukoc Biol 2006, 79:351-362.
46. Spiegel A., Kollet O., Peled A., et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004, 103:2900-2907.
47. Abraham M., Biyder K., Begin M., et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007, 25:2158-2166.
48. Abraham M., Beider K., Wald H., et al. The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation. Leukemia 2009, 23:1378-1388.